AstraZeneca PLC subsidiary Ardea Biosciences Inc.'s gout therapy Zurampic (lesinurad) challenged FDA's regulatory flexibility when secondary clinical endpoints failed to provide the expected backup to the primary endpoint, a surrogate measure that has never been fully tested in a clinical outcomes trial.
Without the supportive scaffolding of secondary measures to provide confidence in the clinical relevance of the primary endpoint, a measure...







